Stock Code: 002424 Stock Abbreviation: ST Bai Ling Announcement No.: 2026-033 Guizhou Bai Ling Enterprise Group Pharmaceutical Co., Ltd. Announcement on the Remuneration Plan for Directors and Senior Management
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Guizhou Bai Ling Enterprise Group Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has formulated the Remuneration Plan for Directors and Senior Management to further standardize the remuneration management of the Company's directors and senior management, incentivize and restrain directors and senior management to perform their duties diligently, and promote the Company's profit growth and sustainable development. In accordance with the "Guidelines for Corporate Governance of Listed Companies," the "Articles of Association," and the "Remuneration Management System for Directors and Senior Management," and in combination with the Company's actual situation, referencing the remuneration levels in the industry and region, the Remuneration Plan for Directors and Senior Management was formulated. The Sixth Board of Directors' Twenty-Sixth Meeting, held on May 12, 2026, reviewed and approved the "Remuneration Plan for Directors and Senior Management." The specific remuneration plan is hereby announced as follows:
I. Target Audience Directors of the Company, Senior Management of the Company